News for Ligand Pharmaceuticals Inc. - Google Finance

LIGAND PHARMACEUTICALS INC. : Ligand to Present at Upcoming Investor ...

Thu, 23 May 2013 12:36:50 GMT

LIGAND PHARMACEUTICALS INC. : Ligand to Present at Upcoming Investor ...
4-traders (press release) - 49 minutes ago

Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly & Co., Spectrum ...

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Investor Investigation over ...

Wed, 22 May 2013 12:32:32 GMT

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Investor Investigation over ...
SBWire (press release) - May 22, 2013

An investigation for current long-term investors in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over potential wrongdoing by certain officers and directors of Ligand Pharmaceuticals Inc. was announced and NASDAQ:LGND stockholders should ...

Ligand Pharmaceuticals Inc. Stock Upgraded (LGND)

Wed, 15 May 2013 09:14:16 GMT

Ligand Pharmaceuticals Inc. Stock Upgraded (LGND)
TheStreet.com - May 15, 2013

LIGAND PHARMACEUTICAL INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago.

Ligand Pharmaceutica Stock Rating Upgraded by TheStreet (LGND) - The Utah People's Post

Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 7c; Approves $5M Buyback

Wed, 08 May 2013 20:17:00 GMT

Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 7c; Approves $5M Buyback
StreetInsider.com (subscription) - May 8, 2013

The Company also expects to repay in full its remaining $18.0 million in debt by August 2014 per the existing repayment schedule.

LIGAND PHARMACEUTICALS INC. : Ligand Acquires Financial Rights to More ...

Tue, 30 Apr 2013 09:59:12 GMT

LIGAND PHARMACEUTICALS INC. : Ligand Acquires Financial Rights to More ...
4-traders (press release) - Apr 30, 2013

Ligand Pharmaceuticals Inc. : Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA.

Ligand acquires biologic development assets from Selexis SA - San Diego Source (subscription)
Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic ... - MarketWatch (press release)

LIGAND PHARMACEUTICALS INC. : Ligand Presents Preclinical Data on ...

Fri, 26 Apr 2013 12:36:41 GMT

LIGAND PHARMACEUTICALS INC. : Ligand Presents Preclinical Data on ...
4-traders (press release) - Apr 26, 2013

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from preclinical studies evaluating Ligand's HepDirect?

Ligand Pharmaceuticals Q1 13 Earnings Conference Call At 4:30 PM ET

Wed, 08 May 2013 19:03:36 GMT

Ligand Pharmaceuticals Q1 13 Earnings Conference Call At 4:30 PM ET
NASDAQ - May 8, 2013

(RTTNews.com) - Ligand Pharmaceuticals Inc ( LGND ) will host a conference call at 4:30 PM ETMay 8, 2013, to discuss its Q1 13 earnings results.

Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled Delafloxacin IV

Tue, 14 May 2013 19:13:53 GMT

Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled Delafloxacin IV
PipelineReview.com (press release) - May 14, 2013

SAN DIEGO, CA, USA I May 14, 2013 I Ligand Pharmaceuticals Incorporated (LGND) announced today that its partner Rib-X Pharmaceuticals, Inc. has initiated a Phase 3 clinical trial of a Captisol-enabled™ intravenous (IV) formulation of delafloxacin for ...

Ligand Pharma To Present At Bank Of America Conference; Webcast At 2:20 PM ...

Wed, 15 May 2013 17:25:19 GMT

Ligand Pharma To Present At Bank Of America Conference; Webcast At 2:20 PM ...
NASDAQ - May 15, 2013

(RTTNews.com) - Ligand Pharmaceuticals Inc. ( LGND ) will present at the Bank of America 2013 Healthcare Conference in Las Vegas.

Cognoptix Test Identifies Alzheimer's Disease via Beta Amyloid Signature in ...

Thu, 23 May 2013 10:28:57 GMT

Cognoptix Test Identifies Alzheimer's Disease via Beta Amyloid Signature in ...
Business Wire (press release) - 2 hours ago

BUSINESS WIRE)--Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer's disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial.